Humana and MemberHealth both issued profit warnings tied to lower than expected earnings from their Part D plans. The reasons are very different but the impact is the same: higher premiums from two of the biggest Medicare plans in 2009. One silver lining for advocates of the program: politically, this is a good time for Medicare plans to be struggling.
Maybe Part D isn’t such a great business for insurers after all.
After two years of almost entirely good news for big Medicare drug plan sponsors, 2008 is off to a rocky...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
Extended-release stimulants will add a new ‘Limitation of Use’ about weight loss in children under 6 years, reflecting concerns about overuse from the Make America Healthy Again commission, a concern multiple studies did not find valid.
